For the quarter ended June 2026, Sight Sciences, Inc. (SGHT Quick QuoteSGHT - Free Report) reported revenue of $23.39 million, up 19.6% over the same period last year. EPS came in at -$0.08, compared to -$0.23 in the year-ago quarter.

The reported revenue represents a surprise of +7.55% over the Zacks Consensus Estimate of $21.75 million. With the consensus EPS estimate being -$0.15, the EPS surprise was +46.67%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Sight Sciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Interventional Dry Eye: $2.68 million compared to the $1.66 million average estimate based on three analysts. The reported number represents a change of +703.3% year over year.
• Revenue- Interventional Glaucoma: $20.71 million compared to the $20.12 million average estimate based on three analysts. The reported number represents a change of +7.7% year over year.
• Gross Profit- Interventional Dry Eye: $2.27 million versus $1.2 million estimated by two analysts on average.
• Gross Profit- Interventional Glaucoma: $19.11 million compared to the $17.2 million average estimate based on two analysts.

View all Key Company Metrics for Sight Sciences here>>>

Shares of Sight Sciences have returned +5.4% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.